Trial · NCT01005810

A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana

NCT01005810, Phase 2, Completed, Medical University of South Carolina; results first posted 2018-11-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana. Trials, record NCT01005810. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01005810

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
NCT number: NCT01005810
Status: Completed
Phases: Phase 2
Enrollment: 116 participants, actual
Lead sponsor: Medical University of South Carolina
Conditions: Cannabis Dependence
Interventions: N-Acetylcysteine, placebo, Contingency Management
First posted: 2009-11-02
Last updated: 2018-11-21
Results first posted: 2018-11-21

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Negative Urine Cannabinoid Tests During Treatment	weekly during treatment, for 8 weeks	\[Total number of negative urine tests per Group divided by the total number of urine tests per Group\]\*100

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Negative Urine Cannabinoid Tests During Treatment	weekly during treatment, for 8 weeks		percentage of negative urine tests	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percentage of Negative Urine Cannabinoid Tests During Treatment	N-Acetylcysteine		40.9		percentage of negative urine tests
Percentage of Negative Urine Cannabinoid Tests During Treatment	Placebo		27.2		percentage of negative urine tests

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	N-Acetylcysteine	58
Overall Study	STARTED	Placebo	58
Overall Study	COMPLETED	N-Acetylcysteine	37
Overall Study	COMPLETED	Placebo	33
Overall Study	NOT COMPLETED	N-Acetylcysteine	21
Overall Study	NOT COMPLETED	Placebo	25

Source ClinicalTrials.gov

Adverse events22

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Upper Respiratory Infection	Infections and infestations	N-Acetylcysteine	11	58	11
other	Upper Respiratory Infection	Infections and infestations	Placebo	8	58	8
other	Abdominal pain	Gastrointestinal disorders	N-Acetylcysteine	2	58	2
other	Abdominal pain	Gastrointestinal disorders	Placebo	1	58	1
other	Conjunctivitis	Infections and infestations	N-Acetylcysteine	1	58	1
other	Conjunctivitis	Infections and infestations	Placebo	0	58	0
other	Decreased appetite	Gastrointestinal disorders	N-Acetylcysteine	1	58	1
other	Decreased appetite	Gastrointestinal disorders	Placebo	3	58	3
other	Drowsiness	Nervous system disorders	N-Acetylcysteine	2	58	2
other	Drowsiness	Nervous system disorders	Placebo	2	58	2

1 to 10 of 22Source ClinicalTrials.gov

See all 22 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	N-Acetylcysteine	0	58
Total, all-cause mortality	Placebo	0	58
Total, other adverse events	N-Acetylcysteine	24	58
Total, other adverse events	Placebo	27	58
Total, serious adverse events	N-Acetylcysteine	0	58
Total, serious adverse events	Placebo	0	58

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DA026777	A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents	GRAY, KEVIN M	MEDICAL UNIVERSITY OF SOUTH CAROLINA	NATIONAL INSTITUTE ON DRUG ABUSE	2009 to 2010

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
N-Acetylcysteine vs Placebo: deaths from any cause	Trial comparisons
N-Acetylcysteine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01005810

GET https://conductscience.org/api/trials/v1/NCT01005810/events?page=2

API reference For AI assistants